Oncology

Latest News

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

By Alana Hippensteele, MA

September 8th 2025

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

By Alana Hippensteele, MA

September 7th 2025

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

By Alana Hippensteele, MA

September 7th 2025

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 9th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 9th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

David Fabrizio Explores Complexities of Surrogate Endpoints in Cancer Clinical Trials

February 6th 2017

David Fabrizio Explores Complexities of Surrogate Endpoints in Cancer Clinical Trials

The FDA has been willing to explore the utilization of surrogate endpoints like tumor response in clinical trials, but it is unclear whether these endpoints correlate with overall survival, said David Fabrizio of Foundation Medicine, Inc. However, he emphasized that overall survival does not necessarily benefit the patient if the additional days gained are not quality days.

Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data

February 6th 2017

Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data

Cancer Outcomes Tracking and Analytics (COTA) focuses on stratifying cancer patients by their many subtypes to understand the different treatments, outcomes, and costs for each, according to Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

February 2nd 2017

Report Commissioned by COA Explores "Murky" World of Pharmacy DIR Fees

Christina Mattina

A white paper commissioned by the Community Oncology Alliance (COA) delved into the practice of “direct and indirect remuneration” fees administered by pharmacy benefit managers and how they could drive up drug prices for Medicare Part D beneficiaries and taxpayers.

February 1st 2017

Pembrolizumab Now Approved for First-Line Treatment of Lung Cancer in Europe and the US

Pembrolizumab (Keytruda) has received green light from the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer.

February 1st 2017

A Focus on Lifestyle and Appropriate Screening During National Cancer Prevention Month

Surabhi Dangi-Garimella, PhD

During the National Cancer Prevention Month, there will be renewed fervor among healthcare providers to ensure individuals pay greater attention toward preventive measures against cancer.

Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria

February 1st 2017

Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria

The criteria to enroll cancer patients in a clinical trial of CAR-T cells vary according to their disease, past therapy, and how far along they are in different treatments, said David L. Porter, MD, of the University of Pennsylvania Health System.

January 31st 2017

Study Recommends Measures to Fill Quality Gaps in Oncology Care

Surabhi Dangi-Garimella, PhD

A multicollaborative study has identified gaps in existing quality measures used by accountable care programs that could result in missed opportunities to improve patient outcomes.

Kim Eason on the Benefits of Patient-Centered Medical Homes

January 31st 2017

Kim Eason on the Benefits of Patient-Centered Medical Homes

Patient-centered medical homes are valuable because they allow insurers to look at the cost of all of the patient’s treatments, services, and physicians throughout the continuum of care, explained Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ.

January 30th 2017

Leaders of Cardiologists, Oncologists Decry Travel Ban

The American College of Cardiology is set to hold its annual meeting in the nation's capital March 17-20, 2017.

January 30th 2017

Need for Switch to Incretins in T2D an Indicator of Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

A retrospective analysis of evidence from prescription data gathered in Belgium and Italy has found that uncontrolled diabetes might be an early sign of pancreatic cancer.

January 29th 2017

Healthy People 2020 Targets Achieved in 30 States for Colorectal Cancer, 28 for Cervical Cancer

Surabhi Dangi-Garimella, PhD

A review of 2013 cancer statistics in the United States by the CDC showed that 67% of people survived at least 5 years after their cancer diagnosis.

Dr Joseph Alvarnas: Innovative Therapies Can Change Oncology Care Paradigm

January 29th 2017

Dr Joseph Alvarnas: Innovative Therapies Can Change Oncology Care Paradigm

Technological advances in cancer care have changed the very process of treatment, as now oncologists can gain more insight into the most effective therapy for each individual patient, according to Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology.

This Week in Managed Care: January 27, 2017

January 27th 2017

This Week in Managed Care: January 27, 2017

This week, the top managed care stories included Aetna and Humana's merger getting blocked, the first Affordable Care Act replacement proposal was unveiled, and an analysis of regional cancer death trends.

January 27th 2017

NICE Endorses Funding for Ibrutinib in Patients With CLL

Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with ibrutinib (Imbruvica) in the United Kingdom.

Dr Carrie Stricker on Why Clinician Voices Are Needed in Health IT Development

January 27th 2017

Dr Carrie Stricker on Why Clinician Voices Are Needed in Health IT Development

The most transformative software companies are those that have seized the opportunity to incorporate clinician and patient voices into the design of their health IT tools, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

January 27th 2017

Coverage of 2016 American Society of Hematology Meeting Available From AJMC®

The American Journal of Managed CareÂ® presents its annual special issue of Evidence-Based Oncologyâ„¢ featuring full coverage of the 58th annual meeting of the American Society of Hematology. CAR T-cell treatments gained notice, as did sessions on patients’ improving quality of life and addressing the high costs of new therapies.

January 26th 2017

First Trial With Universal CAR-T Treatment in Pediatric Leukemia Reports Success

Surabhi Dangi-Garimella, PhD

“Off-the-shelf” chimeric antigen receptor (CAR)-T cells, also known as universal donor cells, were used in 2 young infants with relapsed, refractory acute lymphoblastic leukemia resulted in molecular remission in 28 days in both infants.

January 26th 2017

New Target for Treating Glioblastoma May Increase Survival Time

Researchers from the Peter O’Donnell Jr. Brain Institute and Harold C. Simmons Comprehensive Cancer Center at the University of Texas Southwestern may have found the ultimate drivers of glioblastoma cell proliferation.

January 25th 2017

Study Doubts Impact of Pre-ACA Medicaid Expansion on Access to Cancer Surgery

Surabhi Dangi-Garimella, PhD

Expansion of Medicaid coverage prior to the authorization of the Affordable Care Act (ACA) in 2010 reduced the uninsured rate in New York State, but did not improve access to cancer surgery.

January 25th 2017

Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML

Surabhi Dangi-Garimella, PhD

At the 58th annual meeting of the 58th American Society of Hematology, representatives from 2 national clinical trials, Beat AML and NCI-MATCH, detailed how they were incorporating genomic profiling to assign patients to different treatment arms.

January 25th 2017

JAMA Study Discovers Regional Trends in Cancer-Related Mortality

Surabhi Dangi-Garimella, PhD

An analysis of cancer death records across the country, by researchers at the University of Washington, has identified clusters of counties that had a particularly high rate of mortality depending on the cancer type.

Pam Mangat Discusses ASCO's Plans to Address Challenges of TAPUR Trial

January 25th 2017

Pam Mangat Discusses ASCO's Plans to Address Challenges of TAPUR Trial

Researchers implementing the TAPUR trial have encountered some difficulties, particularly in filling the study cohorts, said Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology (ASCO). However, the ASCO team is dedicated to forging ahead and addressing those challenges.

January 24th 2017

Study Reveals Why Immuno-Oncology Treatments Are Effective in Only a Minority of Patients

Surabhi Dangi-Garimella, PhD

A system-wide immune response, not just a local response limited to the tumor, is what determines successful remission following cancer immunotherapy.

January 23rd 2017

Two Discoveries With Cervical Cancer: Novel Regulatory Genes and the True Mortality Rate

Surabhi Dangi-Garimella, PhD

While one study identified novel mutations and gene amplifications, the other found a wider gap in racial disparity with respect to mortality rates.

January 23rd 2017

Driving Value With Innovative Approaches to Colon Cancer Screening

Although national guidelines call for men and women at average risk for colorectal cancer (CRC) to begin screening for the disease at age 50, by some estimates, compliance is a mere 38%.

January 23rd 2017

Model to Predict Disease Complexity and Costs Associated With AHCT in Acute Leukemia

Surabhi Dangi-Garimella, PhD

Disease status, MUD/MRD donor, myeloablative conditioning regimen, GVHD prophylaxis other than tacrolimus/sirolimus, and Medicare and/or Medicaid as payer are significant predictors for cost of care in patient with acute leukemia who undergo allogenic hematopoietic cell transplant (AHCT).

January 23rd 2017

Healthcare Costs and Utilization After First-Line Therapy for Medicare DLBCL Patients

Christina Mattina

Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who relapsed following first-line treatment had higher rates of healthcare utilization and greater costs than the patients who had not relapsed.

January 23rd 2017

American Society of Hematology's Tenets for Hematologists to Choose Wisely

Surabhi Dangi-Garimella, PhD

Initiated by the American Board of Internal Medicine, Choosing WiselyÂ® is a campaign that has seen participation by a number of different national medical organizations to promote conversations between clinicians and patients to ensure adequate, evidence-based care.

Dr Sean Khozin on FDA Initiative to Analyze Data From Real-World Pipelines

January 23rd 2017

Dr Sean Khozin on FDA Initiative to Analyze Data From Real-World Pipelines

The Information Exchange and Data Transformation initiative at the FDA uses oncology data from not only clinical trials but also electronic health records and biosensors. This patient-centered approach brings research to the real world, as many oncology patients are excluded from clinical trials, said Sean Khozin, MD, MPH, senior medical officer at the FDA.

Jonathan Hirsch Discusses Challenges in Health IT Implementation

January 21st 2017

Jonathan Hirsch Discusses Challenges in Health IT Implementation

The state of current software systems, primarily electronic medical records, is a significant barrier to implementing successful health IT tools, said Jonathan Hirsch, founder and president of Syapse. He also explained some of the solutions developed by Syapse to address these challenges, like improving the software’s integration capabilities and making it more usable for providers.

...

85 86 87 88 89 90 91 92 93

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions